SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition
Metrics: PDF 1978 views | HTML 2242 views | ?
Xin Chen1,*, Yufei Fu2,*, Hongfei Xu1,*, Peng Teng1, Qiong Xie1, Yiran Zhang1, Caochong Yan1, Yiqiao Xu4, Chunqi Li4, Jianying Zhou3, Yiming Ni1 and Weidong Li1
1Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Zhejiang University, Hangzhou, PR China
2Zhejiang Key Laboratory of Gastro-Intestinal Pathophysiology, Zhejiang Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, PR China
3Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University, Hangzhou, PR China
4Hunter Biotechnology, Inc., Hangzhou, PR China
*These authors contributed equally to this work
Weidong Li, email: [email protected]
Yiming Ni, email: [email protected]
Jianying Zhou, email: [email protected]
Keywords: SOX5; EMT; lung adenocarcinoma; prognosis
Received: January 31, 2017 Accepted: October 11, 2017 Published: November 06, 2017
Lung cancer is the leading cause of cancer-related death worldwide. Epithelial-mesenchymal transition (EMT) promotes lung cancer progression and metastasis, especially in lung adenocarcinoma. Sex determining region Y-box protein 5 (SOX5) is known to stimulate the progression of various cancers. Here, we used immunohistochemical analysis to reveal that SOX5 levels were increased in 90 lung adenocarcinoma patients. The high SOX5 expression in lung adenocarcinoma and non-tumor counterparts correlated with the patients’ poor prognosis. Inhibiting SOX5 expression attenuated metastasis and progression in lung cancer cells, while over-expressing SOX5 accelerated lung adenocarcinoma progression and metastasis via EMT. An in vivo zebrafish xenograft cancer model also showed SOX5 knockdown was followed by reduced lung cancer cell proliferation and metastasis. Our results indicate SOX5 promotes lung adenocarcinoma tumorigenicity and can be a novel diagnosis and prognosis marker of the disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.